Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
NKTR-255 comprises polymer-conjugated human IL-15, which binds to the IL-15 receptor and acts as an agonist, potentially resulting in enhanced anti-tumor immune response in combination with antibody therapies (Cancer Res July 1 2019 (79) (13 Supplement) 3265).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Avelumab + NKTR-255||Avelumab NKTR-255||0||1|
|Cetuximab + NKTR-255||Cetuximab NKTR-255||0||1|
|Daratumumab + NKTR-255||Daratumumab NKTR-255||0||1|
|Durvalumab + NKTR-255||Durvalumab NKTR-255||0||1|